Bi-specific antibodies bind to malignant MM cells using an anti-BCMA single-chain variable fragment (scFv), and activate cytotoxic T cells via the other arm containing anti-CD3ε scFV [223]. Here, TNFRSF17 is linked to Miyoshi myopathy.